Research on Solvonis Therapeutics Plc (SVNS:LON) from Turner Pope Investments
Solvonis Therapeutics plc announced that new analyses of its SVN-001 treatment for Alcohol Use Disorder (AUD) show a 67% reduction in heavy drinking days compared to placebo at weeks 17-20, a statistically significant result recognized by European regulators. Indirect cross-trial comparisons suggest SVN-001's efficacy in reducing heavy drinking days surpasses naltrexone and GLP-1 therapies like pemvidutide and semaglutide, with a more patient-friendly four-week dosing regimen. The company is advancing SVN-001 through UK Phase 3 trials with European expansion planned, targeting an estimated 12.5 million people with severe AUD in the UK and EU4, and is developing SVN-002 for the US market.
View Full Research